RainDance Technologies Appoints Kathy Ordoñez as Chief Executive Officer

BILLERICA, Mass.--(BUSINESS WIRE)--

RainDance Technologies, Inc., a genomics company providing leading-edge digital droplet technology supporting the analysis of complex genetic diseases, today announced the appointment of Kathy Ordoñez as Chief Executive Officer. She continues in her current role as Chairman of the Board of Directors. Former CEO Roopom Banerjee has left the Company to pursue other opportunities.

After joining the Board of RainDance in July 2014, Ms. Ordoñez established and led the Science and Innovation Committee for the Board and was named the Company's Chairman of the Board in September 2015. She has subsequently provided guidance to the Company's management team and has worked closely with the Company's investors while leading the Company's product strategy and development efforts.

"Kathy Ordoñez is highly respected in the life sciences and diagnostics industry," said Michael Hunkapiller, Ph.D., a Board Director at RainDance Technologies. "Kathy has brought new focus to RainDance over the past two years, and our board and investors believe her relationship with the team, her creative mindset, and deep industry experience will advance the adoption and reach of RainDance's products and technologies."

Ms. Ordoñez brings more than 30 years of experience in the life sciences and diagnostics industries. As Senior Vice President at Quest Diagnostics, she was initially responsible for leading the company's R&D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services. She joined Quest Diagnostics as part of its acquisition of Celera Corporation in 2011. Ms. Ordoñez was previously the Chief Executive Officer at Celera and a founder of Celera Diagnostics. Under her leadership, Celera became the leading producer of genetic testing products for HIV resistance, cystic fibrosis and high complexity tissue transplantation. Earlier in her career, Ms. Ordoñez held several senior positions at Hoffmann La-Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields.

"It is a privilege to lead the RainDance team, whose members invented and developed key biological applications of droplet technology," said Ms. Ordoñez. "I look forward to building on my relationships with RainDance team members and our business and research partners to launch new products incorporating these innovations over the coming months."

About RainDance Technologies
RainDance Technologies is making complex genetics simple. The company's proprietary droplet technology enables research in areas such as novel non-invasive liquid biopsy. The ultra-sensitive genomic tools provide more accurate, reliable, and cost-effective detection of genetic variations in cancer, inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers.

Stay Connected with RainDance Technologies – Complex Genetics Made Simple
RainDanceTech.com/Twitter | RainDanceTech.com/LinkedIn | RainDanceTech.com/Blog

The RainDrop Digital PCR System and ThunderBolts NGS Enrichment System are for Research Use Only. Not for use in diagnostic procedures.

RainDance Technologies, the RainDance Technologies logo and ThunderBolts, and RainDrop are trademarks of RainDance Technologies, Inc. All other brands may be trademarks of their respective holders.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160629005329/en/